Please follow the links below to learn more about the Institute's new AIDS drug, Immudel™-gp120. The information in the first three sections was written to be accessible to people with a variety of scientific backgrounds.

• Direct Infection Model - initial research indicated that the primary cause of immune system failure was direct infection of T₄ cells by HIV. This section summarizes the direct infection model and why increasing numbers of researchers are questioning it.

• Autoimmune Model - this model proposes that T₄ cell failure and death are primarily caused by an autoimmune attack against the T₄ cells, triggered by the presence of HIV. This section summarizes the autoimmune model and relevant research.

• Details of Immudel-gp120 - detailed description of the design of the Institute's AIDS drug, how it would work, proposed dosing, and possible side effects.

• Pilot Test Results - results of in vitro and in vivo tests for safety and efficacy of Immudel-gp120.

• Expert Review - the responses of experts to the autoimmune model and the design of Immudel-gp120.

• Literature Excerpts - excerpts from some of the scientific papers on which the autoimmune model and drug design are based.

• Medical Hypotheses Article - A scientific article by the Institute detailing the autoimmune model of AIDS and the design of Immudel-gp120, published in the peer-reviewed journal, Medical Hypotheses (Feb. 1999, vol. 52, no. 2, pp. 133-146).

• References - a complete list of the scientific literature references used in the above article; additional references used on this site.